Rabbit-Syndrom unter Olanzapineinnahme

 

 Buy Article Permissions and Reprints

Zusammenfassung

Das Rabbit-Syndrom (RS) ist eine seltene extrapyramidale Nebenwirkung unter neuroleptischer Medikation. Es ist durch unwillkürliche, rhythmische Dyskinesien des Mundes und der Lippen unter Aussparung der Zunge charakterisiert, und wird hauptsächlich unter typischen Neuroleptika beobachtet. Auch unter den atypischen Neuroleptika Risperidon und Aripiprazol ist dieses Syndrom wiederholt beobachtet worden. Wir berichten von einer 74-jährigen Patientin mit einer bipolaren affektiven Störung, welche unter der Einnahme von 20 mg/d Olanzapin ein RS entwickelte. Dies ist unserem Wissen nach der erste Fallbericht eines RS unter Olanzapin.

Abstract

Rabbit syndrome (RS) is a rare extrapyramidal side effect of antipsychotic treatment. It is characterized by involuntary, rhythmic dyskinesias of mouth and lips excluding the tongue, and is most common under typical neuroleptics. There are also several reports of the syndrome in patients with the atypical antipsychotics risperidone and aripiprazole. We report a 74 year-old patient suffering from a bipolar affective disorder, who developed a rabbit syndrome following the intake of 20 mg/d olanzapine. To our knowledge this is the first case report of a RS due to olanzapine.

Literatur

• 1 Villneuve A. The rabbit syndrome: a peculiar extrapyramidal reaction.  Can Psychiatry Assoc J. 1972;  17 69-72
  PubMedGoogle Scholar
• 2 Yassa R, Lal S. Prevalence of the rabbit syndrome.  Am J Psychiatry. 1986;  143 656-657
  PubMedGoogle Scholar
• 3 Chiu H F, Lam L C, Chung D W, Wing Y K, Schum P P. Prevalence of the rabbit syndrome in Hong Kong.  J Nerv Ment Disord. 1993;  181 264-265
  PubMedGoogle Scholar
• 4 Hoy J S, Alexander B D. Rabbit Syndrome secondary to Risperidone.  Pharmacotherapy. 2002;  22 513-515
  CrossrefPubMedGoogle Scholar
• 5 Schwartz M, Beny A, Sharf B. Risperidone-induced rabbit syndrome.  Br J Psychiatry. 1998;  173 267-268
  PubMedGoogle Scholar
• 6 Levin T, Heresco-Levy U. Risperidone-induced rabbit syndrome: an unusual movement disorder caused by an atypical antipsychotic.  Eur Neuropsychopharm. 1999;  9 137-139
  PubMedGoogle Scholar
• 7 Mendhekar D N. Aripiprazole-induced rabbit syndrome.  Austr New Zea J Psychiatry. 2004;  38 561
  PubMedGoogle Scholar
• 8 Durst R, Katz G, Zislin J, Raskin S, Kalman I. Rabbit syndrome treated with olanzapine.  Br J Psychiatry. 2000;  176 193
  CrossrefPubMedGoogle Scholar
• 9 Fornazzari L, Ichise M, Remington G, Smith I. Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.  J Psychiatry Neurosci. 1991;  16 227-229
  PubMedGoogle Scholar
• 10 Schwartz M, Hocherman S. Antipschotic-induced rabbit syndrome: epidemiology, management and pathophysiology.  CNS Drugs. 2004;  18 213-220
  PubMedGoogle Scholar
• 11 Nishimura K, Tuska M, Horikawa N. Withdrawal-emergent rabbit syndrome during dose reduction of risperodone.  Eur Neuropsychopharmacol. 2001;  11 323-324
  CrossrefPubMedGoogle Scholar
• 12 Kamijo Y, Soma K, Fukuda M, Asari Y, Ohwada T. Rabbit syndrome following phenol ingestion.  J Toxicol Clin Toxicol. 1999;  37 509-511
  CrossrefPubMedGoogle Scholar
• 13 Villeneuve A, Lajeunesse C. Clinical aspects of tardive dyskinesias induced by neuoleptics.  Encephale. 1988;  14 S209-214
  PubMedGoogle Scholar
• 14 Goetz C G, Blasucci L M, Leurgans S, Pappert E J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patient.  Neurology. 2000;  55 789-794
  CrossrefPubMedGoogle Scholar
• 15 Marsh L, Lyketsos C, Reich S C. Olanzapine for the treatment of psychosis with parkinson's disease and dementia.  Psychosomatics. 2001;  42 477-481
  CrossrefPubMedGoogle Scholar
• 16 Molho E, Factor S. Worsening of motor features of Parkinson's disease with olanzapine.  Mov Disord. 1998;  13 256
  PubMedGoogle Scholar
• 17 Jemenez-Jemenez F, Tallo-Baranco O, Pareva O. Olanzapine can worsen parkinsonism.  Neurology. 1998;  50 1183-1184
  PubMedGoogle Scholar
• 18 Ciudad A, Montes J M, Olivares J M, Gomez J C. Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.  Eur Psychiatry. 2004;  19 358-65
  CrossrefPubMedGoogle Scholar
• 19 Kopf A, Köster J, Schulz A, Krömker H, Becker T. Life threatening neuroleptic malignant syndrome due to olanzapine.  Psychiat Prax. 2003;  30 279-282
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Mancini F, Tassorelli C, Martignoni E, Moglia A, Nappi G, Cristina S, Pacchetti C. Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.  Clin Neuropharmacol. 2004;  27 33-37
  PubMedGoogle Scholar
• 21 Juncos J L, Roberts V J, Evatt M L, Jewart R D, Wood C D, Potter L S, Yeung P P. Quetiapine improves psychotic symptoms and cognistion in Parkinson's disease.  Mov Disord. 2004;  19 29-35
  CrossrefPubMedGoogle Scholar
• 22 Fernandez H H, Trieschmann M E, Burke M A, Jacques C, Friedman J H. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.  Mov Disord. 2003;  18 510-514
  CrossrefPubMedGoogle Scholar
• 23 Pollak P. Psychic disorders.  Rev Neurol. 2002;  158 S125-131
  PubMedGoogle Scholar
• 24 Reddy S, Factor S A, Molho E S, Feustel P J. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.  Mov Disord. 2002;  17 676-681
  CrossrefPubMedGoogle Scholar
• 25 Targum S D, Abbott J L. Efficacy of quetiapine in Parkinson's patients with psychosis.  J Clin Psychopharmacol. 2000;  20 54-60
  CrossrefPubMedGoogle Scholar
• 26 Sethi S, Bhargava S C. Clozapine-induced rabbit syndrome.  J Clin Psychiatry. 2003;  64 219
  PubMedGoogle Scholar

Dr. med. Michael Sabolek

Abt. Psychiatrie II der Universität Ulm · Bezirkskrankenhaus Günzburg

Ludwig-Heilmeyer-Straße 2

89312 Günzburg

Email: michael.sabolek@medizin.uni-ulm.de